Admission Date:  [**2148-8-11**]              Discharge Date:   [**2148-8-22**]  Date of Birth:  [**2089-11-5**]             Sex:   M  Service: MEDICINE  Allergies: Patient recorded as having No Known Allergies to Drugs  Attending:[**Known firstname 6169**] Chief Complaint: Induction chemotherapy for MDS transformed to AML  Major Surgical or Invasive Procedure: None  History of Present Illness: Mr. [**Known lastname 66632**] is a 58 year old male with a history of MDS /myeloproliferative disease overlap syndrome that has transformed to AML.
He was admitted to the Heme Malignancies service on [**2148-8-11**] for initiation of induction chemotherapy.
Skin: His right leg, he has a skin graft that is healing well, cutaneous ulcer approximately 2 x 3 cm that is granulating well.
Pertinent Results: [**2148-8-11**] 08:36PM   POTASSIUM-3.5 [**2148-8-11**] 08:36PM   LD(LDH)-467* [**2148-8-11**] 08:36PM   PHOSPHATE-4.4# URIC ACID-9.1* [**2148-8-11**] 08:36PM   WBC-55.7* RBC-3.20* HGB-9.3* HCT-26.2* MCV-82 MCH-29.1 MCHC-35.5* RDW-18.7* [**2148-8-11**] 08:36PM   NEUTS-23* BANDS-2 LYMPHS-8* MONOS-41* EOS-1 BASOS-2 ATYPS-0 METAS-1* MYELOS-2* BLASTS-20* [**2148-8-11**] 08:36PM   PLT COUNT-17*# [**2148-8-11**] 07:30PM URINE  COLOR-Yellow APPEAR-Clear SP [**Last Name (un) 155**]-1.010 [**2148-8-11**] 07:30PM URINE  BLOOD-NEG NITRITE-NEG PROTEIN-NEG GLUCOSE-NEG KETONE-NEG BILIRUBIN-NEG UROBILNGN-NEG PH-5.0 LEUK-NEG [**2148-8-11**] 11:45AM   GLUCOSE-102 UREA N-24* CREAT-1.2 SODIUM-137 POTASSIUM-3.7 CHLORIDE-102 TOTAL CO2-23 ANION GAP-16 [**2148-8-11**] 11:45AM   ALT(SGPT)-23 AST(SGOT)-31 ALK PHOS-178* [**2148-8-11**] 11:45AM   ALBUMIN-3.1* CALCIUM-7.9* PHOSPHATE-2.5* MAGNESIUM-1.5* URIC ACID-8.4* [**2148-8-11**] 11:45AM   WBC-97.2* RBC-2.82* HGB-8.2* HCT-24.2* MCV-86 MCH-29.2 MCHC-34.0 RDW-19.0* [**2148-8-11**] 11:45AM   PLT COUNT-40* .
These findings could represent cellulitis in the appropriate clinical setting or could be due to radiation therapy.
Brief Hospital Course: He was found to have C diff colitis on admission, so his induction therapy was delayed a few days.
The patient was administered his first treatment with MEC (mitoxantrone, etoposide, and Ara-C) on [**2148-8-13**].
He initially required blood pressure support with Levophed.
The Renal team was consulted, and the patient underwent hemodialysis given his persistently elevated potassium and episodes of widened QRS and transient complete heart block on EKG/telemetry.
The patient also had a coagulopathy, and he requried transfusion of FFP prior to placement of his hemodialysis catheter.
During his admission, he required more than seven packed red blood cell transfusions, and eight platelet transfusions.
With consult from Neuro, Mr. [**Known lastname **] was assessed to have suffered hypoxic brain injury secondary to his code on [**8-18**] and he had not improved his mental status beyond corneal blink and moving eyes for more than 48 hours after he suffered PEA.
His wife decided to withdrawl ventilatory support due to his poor prognosis and the fact that he was very unlikely to regain any functional status.
Medications on Admission: His medicines have included allopurinol 300 daily, hydroxyurea, recently increased to 3 g daily, prednisone 20 mg PO qd, Voriconazole 200 mg PO BID, Timolol 0.25% eye drops [**Hospital1 **], Bactrim three times a week, ACV 600 mg PO TID, and PCN 500 mg PO TID.
